Docivyx is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How do you pay?

How to pay the least

Given by your care team

Billed by the clinic

Docivyx is given by a doctor or nurse, not picked up at a pharmacy.

  1. Ask your care team or your plan what you’d pay before your visit.

Compare every option

Question
Brand nameDocivyx
Authorized genericdocetaxel
Regular genericdocetaxel
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Docivyx?
The original
–
–

Brand nameThe maker’s card

AVYXASSIST Copay Assistance Program

Savings card from AVYXA Pharma, LLC

Docivyx’s maker has a savings program. Its page doesn’t list a dollar amount.

Sign up on docivyx.com 

Or call 1-866-939-8927.

From the maker’s site, checked November 2, 2026. Check the maker’s page for who can use it.

Authorized genericNot sold

There isn’t one. An authorized generic is Docivyx itself, from the same company, sold without the brand name, and usually for less. For now Docivyx is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

DOCIVYX is a microtubule inhibitor indicated for:

  • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
  • Non-small Cell Lung Cancer (NSCLC):single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
  • Castration- Resistant Prostate Cancer (CRPC): with prednisone in metastatic CRPC
  • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN

Source: the FDA label for Docivyx (Avyxa Pharma, LLC), July 15, 2025. Full label on DailyMed 

Good to know